Role of Genetic Polymorphisms in Individual Variations in Drug Response
Keywords:
Pharmacogenetics, Genetic Polymorphisms, Drug Metabolism, CYP450, Pharmacogenomics, Personalized Medicine, Adverse Drug Reactions, Precision TherapeuticsAbstract
Interindividual variability in drug response remains a major challenge to safe and effective pharmacotherapy. Genetic polymorphisms in genes encoding drug-metabolizing enzymes, transporters, therapeutic targets, and immune recognition proteins contribute to differences in drug exposure, efficacy, and adverse reactions. This narrative review synthesizes published international evidence concerning the molecular basis and clinical relevance of pharmacogenetic variation. Six domains are considered: the biological foundations of polymorphism; cytochrome P450 variation; cardiovascular pharmacogenetics; oncology and analgesic prescribing; HLA-associated hypersensitivity; and clinical implementation. Well-established gene–drug associations include CYP2C19 with clopidogrel, CYP2C9 and VKORC1 with warfarin, SLCO1B1 with statin-associated toxicity, TPMT and NUDT15 with thiopurines, DPYD with fluoropyrimidines, and selected HLA alleles with severe drug reactions. Although preemptive testing has demonstrated clinical promise, not every genetic association is actionable, and the predictive value of genetic results depends on clinical context, ancestry-inclusive test design, concurrent medicines, and physiological factors. Integrating validated pharmacogenetic guidance with clinical judgment offers an important route toward more individualized prescribing.
Downloads
References
Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526, 343–350. https://doi.org/10.1038/nature15817
Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. Nature, 429, 464–468. https://doi.org/10.1038/nature02626
Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., & Klein, T. E. (2021). An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 110(3), 563–572. https://doi.org/10.1002/cpt.2350
Caudle, K. E., et al. (2017). Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium. Genetics in Medicine, 19(2), 215–223. https://doi.org/10.1038/gim.2016.87
Swen, J. J., et al. (2011). Pharmacogenetics: From bench to byte—An update of guidelines. Clinical Pharmacology & Therapeutics, 89(5), 662–673. https://doi.org/10.1038/clpt.2011.34
Crews, K. R., et al. (2021). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clinical Pharmacology & Therapeutics, 110(4), 888–896. https://doi.org/10.1002/cpt.2149
Crews, K. R., et al. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clinical Pharmacology & Therapeutics, 95(4), 376–382. https://doi.org/10.1038/clpt.2013.254
Bousman, C. A., et al. (2023). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51–68. https://doi.org/10.1002/cpt.2903
Lee, C. R., et al. (2022). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics, 112(5), 959–967. https://doi.org/10.1002/cpt.2526
Mega, J. L., et al. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360(4), 354–362. https://doi.org/10.1056/NEJMoa0809171
Simon, T., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. The New England Journal of Medicine, 360(4), 363–375. https://doi.org/10.1056/NEJMoa0808227
Paré, G., et al. (2010). Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. The New England Journal of Medicine, 363(18), 1704–1714. https://doi.org/10.1056/NEJMoa1008410
International Warfarin Pharmacogenetics Consortium. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine, 360(8), 753–764. https://doi.org/10.1056/NEJMoa0809329
Pirmohamed, M., et al. (2013). A randomized trial of genotype-guided dosing of warfarin. The New England Journal of Medicine, 369(24), 2294–2303. https://doi.org/10.1056/NEJMoa1311386
SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy—A genomewide study. The New England Journal of Medicine, 359(8), 789–799. https://doi.org/10.1056/NEJMoa0801936
Relling, M. V., et al. (2019). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clinical Pharmacology & Therapeutics, 105(5), 1095–1105. https://doi.org/10.1002/cpt.1304
Maillard, M., et al. (2026). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. Clinical Pharmacology & Therapeutics, 119(4), 916–927. https://doi.org/10.1002/cpt.70209
Amstutz, U., et al. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clinical Pharmacology & Therapeutics, 103(2), 210–216. https://doi.org/10.1002/cpt.911
Deenen, M. J., et al. (2016). Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: A safety and cost analysis. Journal of Clinical Oncology, 34(3), 227–234. https://doi.org/10.1200/JCO.2015.63.1325
Kimmel, S. E., et al. (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. The New England Journal of Medicine, 369(24), 2283–2293. https://doi.org/10.1056/NEJMoa1310669
Mallal, S., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine, 358(6), 568–579. https://doi.org/10.1056/NEJMoa0706135
Chung, W.-H., et al. (2004). A marker for Stevens–Johnson syndrome. Nature, 428, 486. https://doi.org/10.1038/428486a
Chessman, D., et al. (2008). Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 28(6), 822–832. https://doi.org/10.1016/j.immuni.2008.04.020
Phillips, E. J., et al. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clinical Pharmacology & Therapeutics, 103(4), 574–581. https://doi.org/10.1002/cpt.1004
Saito, Y., et al. (2016). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen B genotype and allopurinol dosing: 2015 update. Clinical Pharmacology & Therapeutics, 99(1), 36–37. https://doi.org/10.1002/cpt.161
Swen, J. J., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, 401(10374), 347–356. https://doi.org/10.1016/S0140-6736(22)01841-4
Dunnenberger, H. M., et al. (2015). Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annual Review of Pharmacology and Toxicology, 55, 89–106. https://doi.org/10.1146/annurev-pharmtox-010814-124835
Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464–467. https://doi.org/10.1038/clpt.2010.279
Hershfield, M. S., et al. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clinical Pharmacology & Therapeutics, 93(2), 153–158. https://doi.org/10.1038/clpt.2012.209
Gammal, R. S., et al. (2022). The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms. Clinical Pharmacology & Therapeutics, 111(5), 1007–1021. https://doi.org/10.1002/cpt.2557
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Neha Priyadarshini Chaudhary

This work is licensed under a Creative Commons Attribution 4.0 International License.